Severe Hepatitis Complicating Olmesartan Enteropathy: A Case Report.

Autor: Tan R; Department of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia., Abasszade JH; Department of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia., Dhillon H; Department of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia., Kuan CC; Department of Anatomical Pathology, Monash Health, Melbourne, VIC, Australia., Worland T; Department of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia., Tabatabai S; Department of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia.
Jazyk: angličtina
Zdroj: Case reports in gastroenterology [Case Rep Gastroenterol] 2024 Apr 25; Vol. 18 (1), pp. 238-243. Date of Electronic Publication: 2024 Apr 25 (Print Publication: 2024).
DOI: 10.1159/000538552
Abstrakt: Introduction: Olmesartan, an angiotensin II receptor antagonist, is associated with an uncommon complication of enteropathy that presents insidiously, usually months to years after initial commencement of anti-hypertensive therapy which can be dose-dependent. It has a variable spectrum of clinical presentation but commonly presents as a moderate to severe malabsorptive process with potential severe complications related to poor end-organ perfusion. Lymphocytic gastritis and microscopic colitis are often noted in patients presenting with olmesartan-induced enteropathy; however, hepatic involvement has been less frequently observed.
Case Presentation: We illustrate a case of a 43-year-old female presenting with 2 weeks of profuse non-bloody diarrhea in the context of olmesartan enteropathy which was complicated by an acute severe ischemic and enteropathic hepatopathy.
Conclusion: Our case prompts clinicians to maintain a high index of suspicion in cases presenting with a seronegative enteropathy and concurrent acute liver injury while on olmesartan therapy. Cessation of olmesartan therapy resulted in prompt resolution of diarrheal symptoms and normalization of the acute transaminitis on subsequent three-week follow-up.
Competing Interests: The authors declare that there are no conflicts of interest regarding the publication of this article.
(© 2024 The Author(s). Published by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje